Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVP04-UPenn
- Development stage
- Preclinical
- Lead developer
- Avipep
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AVP04-UPenn is a preclinical antibody-drug conjugate (ADC) being developed by Avipep in collaboration with the University of Pennsylvania. The drug utilizes Avipep's proprietary "Avibody" technology, which consists of high-affinity, small-format antibody fragments, specifically a diabody (scFv dimer). AVP04 is derived from the CC49 monoclonal antibody and targets Tumor-Associated Glycoprotein 72 (TAG-72), a cell-surface antigen highly expressed in various solid tumors, including colorectal, ovarian, and prostate cancers. The AVP04-UPenn program is positioned within the immunotherapy space, leveraging the diabody's rapid tumor penetration and clearance characteristics to deliver a cytotoxic payload specifically to TAG-72-expressing malignant cells while minimizing systemic exposure.
- Other names
- AVP-04-UPennAVP04-UPennAVP 04-UPenn
02
Targets
TAG-72
Beyond the preview
Go deeper on AVP04-UPenn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVP04-UPenn.